2021
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis
Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Chaar C, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American Journal Of Hematology 2021, 96: 471-479. PMID: 33476420, PMCID: PMC8013588, DOI: 10.1002/ajh.26102.Peer-Reviewed Original ResearchConceptsProphylactic-dose anticoagulationAntiplatelet therapyHospital deathCumulative incidenceMultivariable regression modelsHospital mortalityHospitalized adult COVID-19 patientsAdult COVID-19 patientsPropensity score-matched patientsPropensity score-matched analysisCOVID-19Intensive antithrombotic therapyIntermediate-dose anticoagulationCohort of patientsCOVID-19 patientsPatient-specific covariatesAnticoagulation cohortAspirin cohortDose anticoagulationAntithrombotic therapyThrombotic complicationsHospitalized patientsPrimary outcomeIllness severityRegression models
2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients
2018
Transient bacteremia induced by dental cleaning is not associated with infection of central venous catheters in patients with cancer
Usmani S, Choquette L, Bona R, Feinn R, Shahid Z, Lalla RV. Transient bacteremia induced by dental cleaning is not associated with infection of central venous catheters in patients with cancer. Oral Surgery Oral Medicine Oral Pathology And Oral Radiology 2018, 125: 286-294. PMID: 29428697, PMCID: PMC5944361, DOI: 10.1016/j.oooo.2017.12.022.Peer-Reviewed Original ResearchConceptsCentral venous cathetersCVC-related infectionsAbsolute neutrophil countBlood culture resultsDental cleaningBloodstream infectionsNeutrophil countVenous cathetersCulture resultsIncidence of bacteremiaAntibiotic prophylaxisPeriodontal screeningPeriodontal statusTransient bacteremiaMedical recordsBlood culturesPatientsBacteremiaPSR scoresOral microorganismsInfectionCancerRecording scoresCatheterBaseline
2010
Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing
Roper N, Storer B, Bona R, Fang M. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. Journal Of Molecular Diagnostics 2010, 12: 283-291. PMID: 20228265, PMCID: PMC2860463, DOI: 10.2353/jmoldx.2010.090110.Peer-Reviewed Original ResearchConceptsPharmacogenetics-based dosing algorithmDosing algorithmInternational Warfarin Pharmacogenetics ConsortiumPercentage of patientsNarrow therapeutic windowDiverse ethnic populationsMaintenance dosesProspective trialWarfarin dosesWarfarin dosingPrescribed drugsPharmacogenetic testingWarfarin metabolismIWPC algorithmClinical utilityDosing rangeTherapeutic windowWarfarinGenetic testingPatientsGenetic polymorphismsExternal validationEthnic populationsService populationCYP2C9